Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
52 participants
INTERVENTIONAL
2004-11-30
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
XL999 Administered Intravenously to a Subject With Advanced Malignancies
NCT01945164
Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
NCT00086528
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
NCT00491699
Study of XL820 in Adults With Solid Tumors
NCT00129571
Maintenance Study on the Long Term Safety of XL999
NCT00955084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XL999
XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cancer that has progressed on currently available therapies
* Life expectancy of \>3 months
* Adequate bone marrow, liver, and kidney function
* Willing to use accepted method of contraception during the course of the study
* Negative pregnancy test (females)
* Written informed consent
Exclusion Criteria
* Radiotherapy within 4 weeks of the start of treatment
* Subjects with known brain metastasis
* Uncontrolled medical disorder such as infection or cardiovascular disease
* Subjects known to be HIV positive
* Pregnant or breastfeeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Symphony Evolution, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Symphony Evolution, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Woodard, MD
Role: STUDY_DIRECTOR
Exelixis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Case Western Reserve University, Univserzity Hospitals of Cleveland
Cleveland, Ohio, United States
Cancer Therapy and Research Center, Institute for Drug Development
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XL999-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.